Sanofi Expands Regeneron Alliance With Four Long-Acting Antibodies, Paying $1B Upfront With Up To $7B In Milestones; Costs And Profits Shared Equally

Sanofi has expanded its alliance with Regeneron by adding four long-acting antibodies, including the clinical-stage REGN20423. The agreement includes an upfront payment of $1 billion and potential milestone payments of up to $7 billion. Both companies will share development and commercialization costs equally, along with any future profits.